CAMBRIDGE, Mass. & SHANGHAI, China--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Shanghai GenePharma Co., Ltd, a leading siRNA supplier in China, announced today that Alnylam has granted Shanghai GenePharma a non-exclusive world-wide license to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers fundamental aspects of the structure and uses of RNAi products including their use to mediate RNAi in mammalian cells and of RNAi-related mechanisms.
